Etihad Cargo || Pharma Corridor 2.0
PRMA Consulting - A holistic approach to market access in emerging markets
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

Driving value creation through medical affairs in China

Summary:

After more than three decades of fast economic growth, China has entered the “new normal” stage, marked by a moderate and stable domestic GDP growth rate. Healthcare has been elevated to a national level agenda by the current leadership with the releasing of “China Health 2030”.

In addition, “Made in China 2025” (shown in Figure 1) has also demonstrated Chinese government’s mission to foster innovation while continuing to enhance drug safety and improve healthcare service quality.

Download '.pdf' Format of the whitepaper.

Download Whitepapers
Latest Issue
Get instant
access to our latest e-book
Eppendorf Centrifuge 5910 Ri Catalent  Asia-Pacific Clinical Supply Solutions Meco - 90 years